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Concentrations of Direct Oral Anticoagulants
S. Bloemen1,2, S. Zwaveling1,2, J. Douxfils3, T. Peters1,2, R. 
Wagenvoord1,2, H.C. Hemker1,2, F. Mullier3,4, B. de Laat1,2, M. 
Roest1,2, R. Kremers1,2
1Synapse Research Institute, CARIM, Maastricht University, Maastricht, The 
Netherlands, 2CARIM, Maastricht University, Department of Biochemistry, 
Maastricht, The Netherlands, 3Namur Research Institute for Life Sciences, University 
of Namur, Department of Pharmacy, Namur, Belgium, 4Université Catholique 
de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and 
Hemostasis Center, Yvoir, Belgium
Background: Direct oral anticoagulants (DOACs) are commonly pro-
vided without monitoring. However, reliable assays to measure DOAC 
levels and activity in emergency situations are needed. We developed 
a test based on the inhibition of α2macroglobulin-thrombin (α2M-IIa) 
by dabigatran (DAB) and of α2M-factor Xa (α2M-Xa) by rivaroxaban 
(RIV), making it possible to evaluate both DOAC classes in combina-
tion with thrombin generation (TG).
Aims: To quantify DOAC levels and activity in plasma.
Methods: Consenting patients using RIV (n=50) and DAB (n=28) 
were included. TG was performed in platelet poor plasma (5 pM 
tissue factor), with idarucizumab in calibrator wells for DAB sam-
ples. The new DOAC assays measured the effect of diluted plasma 
samples on Z-Gly-Gly-Arg-AMC conversion by α2M-Xa or α2M-IIa. 
The slopes of these curves were compared to a reference curve 
with known DOAC concentrations. DOAC levels were also esti-
mated by ‘classical’ assays. Spearman correlation coefficients were 
determined.
Results: A concentration of 30 nM α2M-Xa or α2M-IIa was optimal to 
measure 50-500 nM RIV/DAB and 90 nM α2M-Xa or 70 nM α2M-IIa, 
respectively were optimal for 500-1000 nM RIV/DAB (Fig.1).
The intra- and inter-assay CV were below 2.5 % and 5% (n=2). Both 
the RIV and DAB assay correlated with TG parameters. The RIV 
assay correlated with ‚classical’ assays and had a very good corre-
lation with Biophen DiXaI. The DAB assay did not correlate with 
hemoclot thrombin inhibitor (probably since DAB concentrations 
were too low), but showed variable correlation with the other as-
says (Table1).
Conclusions: The new DOAC assays show good correlations with 
other assays that were confirmed to accurately assess DOAC 
levels (particularly the RIV assay with the Biophen DiXaI, which 
had the best correlation with mass spectrometry). Our assay can 
simultaneously evaluate DOAC concentrations as well as the 
DOACs effect on thrombin generation, providing an overview of 
the anticoagulation status of a patient in relation to circulating 
DOAC levels. 
F I G U R E  1 Dose-response of several DOAC concentrations at 
chosen α2M-Xa and α2M-IIa concentrations
T A B L E  1 Correlation (Spearman) of rivaroxaban or dabigatran concentration (as determined by the new assay) with TG and other calibrated 
assays
 Assay
Correlation 
coefficient p-value  Assay
Correlation 
coefficient p-value
Rivaroxaban Calibrated prothrom-
bin time (ng/ml)
0.468 0.002 Dabigatran Activated partial thrombo-
plastin time (s)
0.581 0.002
 Dilute Russel viper 
venom time (s)
0.760 0.000  Dilute Russel viper venom 
time (s)
0.649 0.001
 Biophen DiXaI (ng/ml) 0.915 0.000  Hemoclot thrombin inhibitor 
(ng/ml)
0.391 0.097
 TG endogenous 
thrombin 
potential(nM.min)
-0.525 0.000  Ecarin chromogenic assay 
(ng/ml)
0.591 0.001
 TG Peak (nM) -0.550 0.000  TG endogenous thrombin 
potential(nM.min)
-0.323 0.100
 TG lag time (min) 0.671 0.000  TG Peak (nM) -0.354 0.201
 TG time-to-peak (min) 0.702 0.000  TG lag time (min) 0.423 0.028
     TG time-to-peak (min) 0.339 0.084
